The aetiology of essential hypertension, a disease prevalent in cultured societies, is unknown. However, much evidence suggests that abnormal sodium metabolism has a critical role—this has led to the hypothesis that an increase in the circulating concentration of an inhibitor of (Na+ + K+) ATPase is responsible for the increased peripheral vascular resistance in essential hypertension1. Evidence for relatively high levels of a Na+ pump inhibitor in essential hypertension has come from bioassay and cytochemical assays of plasma and urine from normotensive and hypertensive individuals2,3. There is also evidence for increased plasma levels of a Na+ pump inhibitor in some animal models (for example, renal and deoxycorticosterone acetate (DOCA) models) of hypertension4. Nevertheless, direct biochemical determination of (Na+ + K+) ATPase inhibition by this substance has not yet been reported. We demonstrate here, with a kinetic (Na+ + K+) ATPase assay, a highly significant correlation between levels of a plasma inhibitor of (Na+ + K+)ATPase activity and mean arterial blood pressure (MAP) in normotensive and hypertensive individuals. These data provide evidence for the involvement of a circulating Na+ pump inhibitor in the genesis of essential hypertension. Moreover, our assay methods may be useful for the isolation and characterization of this inhibitor.
Subscribe to Journal
Get full journal access for 1 year
only $3.90 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Blaustein, M. P. Am. J. Physiol. 232, C165–C173 (1977).
MacGregor, G. A. et al. Br. med. J. 283, 1335–1357 (1981).
Poston, L. et al. Br. med. J. 282, 847–849 (1981).
Pamnani, M. B., Huot, S., Buggy, J., Clough, D. & Haddy, F. Hypertension 3, Suppl. Ii, II-96–Ii-101 (1981).
Akera, T., Choi, Y. R. & Yamamoto, S. in Na, K-ATPase, Structure and Kinetics (eds Skou, J. C. & Norby, J. G.) 405–420 (Academic, New York, 1979).
Fagan, J. B. & Racker, E. Biochemistry 16, 152–158 (1977).
Quist, E. E. & Hokin, L. E. Biochim. biophys. Acta 511, 202–212 (1978).
Cantley, L. C. et al. J. biol Chem. 252, 7421–7423 (1977).
Jorgensen, P. L. Biochim. biophys. Acta 356, 36–52 (1974).
Gruber, K. A., Whitaker, J. M. & Buckalew, V. M. Nature 287, 743–745 (1980).
Gruber, K. A., Rudel, L. L. & Bullock, B. C. Hypertension 4, 348–354 (1982).
Losse, H., Wehmeyer, H. & Wessels, F. Klin. Wschr. 38, 393–395 (1960).
Edmondson, R. P. S., Thomas, R. D., Hilton, P. J., Patrick, J. & Jones, N. F. Lancet i, 1003–1005 (1975).
Blaustein, M. P. Clin. exp. Hypertension 3, 173–178 (1981).
Blaustein, M. P. in Recent Advances in Hypertension Mechanisms (eds Villareal, H. & Sambhi, M.) (in the press).
Lang, S. & Blaustein, M. P. Circulation Res. 46, 463–470 (1980).
Filo, R. S., Bohr, D. F. & Rüegg, J. C. Science 147, 1581–1583 (1972).
Folkow, B. & Neil, E. Circulation, 560–583 (Oxford University Press, 1971).
Nakazato, Y., Ohga, A. & Onoda, Y. J. Physiol., Land. 278, 45–54 (1978).
Leitz, F. H. & Stefano, F. J. E. Eur. J. Pharmac. 11, 278–285 (1970).
de Wardener, H. E. & MacGregor, G. A. Kidney Int. 18, 1–9 (1980).
de Wardener, H. E. Am. J. Physiol. 235, F163–F173 (1978).
Zadik, Z., Hamilton, B. P. & Kowarski, A. A. J. clin Endocr. Metab. 50, 842–845 (1980).
Kowarski, A. A., Edwin, C. J., Akesode, A. P., Pitrowski, L. S. & Hamilton, B. P. Johns Hopkins med. J. 142, 35–38 (1978).
King, E. J. Biochem. J. 26, 292–297 (1932).
Bradford, M. M. Analyt. Biochem. 72, 248–254 (1976).
About this article
Cite this article
Hamlyn, J., Ringel, R., Schaeffer, J. et al. A circulating inhibitor of (Na+ + K+) ATPase associated with essential hypertension. Nature 300, 650–652 (1982). https://doi.org/10.1038/300650a0
Conformational states of the pig kidney Na+/K+-ATPase differently affect bufadienolides and cardenolides: A directed structure-activity and structure-kinetics study
Biochemical Pharmacology (2020)
Biomedicine & Pharmacotherapy (2020)
Cell Calcium (2020)
Neuroprotective and tumoricidal activities of cardiac glycosides. Could oleandrin be a new weapon against stroke and glioblastoma?
International Journal of Neuroscience (2018)
Neurochemical Journal (2018)